Chimerix (NASDAQ:CMRX) is set to announce its earnings results before the market opens on Wednesday, February 28th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
Chimerix (NASDAQ CMRX) opened at $4.97 on Wednesday. The company has a market cap of $234.22, a P/E ratio of -3.48 and a beta of 1.42. Chimerix has a 1 year low of $4.17 and a 1 year high of $6.64.
Several equities analysts recently commented on CMRX shares. ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Friday, November 10th. HC Wainwright started coverage on shares of Chimerix in a research report on Friday, February 2nd. They issued a “buy” rating and a $10.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered shares of Chimerix from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $7.06.
In related news, insider Linda M. Richardson sold 19,833 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.40% of the company’s stock.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.